# ulcerative colitis (UC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 57738
- Completion tokens: 37333
- Reasoning tokens: 17807
- Total tokens: 95071
- API requests reported: 4
- Elapsed seconds: 87.935
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 3/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants a comprehensive biological interpretation of a differential expression analysis comparing ulcerative colitis (UC) colonic mucosa versus healthy controls. Let me carefully review the data.

**Dataset overview:**
- 100 unique genes selected (from 175 input rows; 43 duplicated probes/genes)
- 40 upregulated, 60 downregulated
- All FDR ≤ 0.01, all P ≤ 0.05
- Effect metric: log2FC

**Top upregulated genes (by log2FC magnitude):**
- SLC6A14 (log2FC = +4.85) — amino acid transporter, well-known UC marker
- DUOX2 (+4.67) — NADPH oxidase producing H2O2, mucosal antimicrobial defense
- MMP3 (+4.64) — matrix metalloproteinase, tissue remodeling/inflammation
- CHI3L1 (+4.59) — chitinase 3-like 1, neutrophil/macrophage marker
- S100A8 (+3.80) — calprotectin component
- CXCL1 (+3.46) — neutrophil chemokine
- SERPINB5 (+3.29) — maspin
- VNN1 (+3.20) — pantetheinase
- TRIM29 (+2.83) — epithelial stress
- IL1RN (+2.88) — IL-1 receptor antagonist
- CXCL2 (+2.80) — neutrophil chemokine
- SOCS3 (+2.79) — JAK/STAT negative regulator
- PRRX1 (+2.91)
- DUOXA2 (+2.89)
- CTLA4 (+2.62)
- TNC (+2.58)
- CXCL3 (+2.33)
- PI3 (+2.21)
- IFI16 (+1.39)

**Top downregulated genes:**
- AQP8 (-4.42) — aquaporin, water/bile transport
- SLC51A (-3.71) — OSTα, bile acid transporter
- HMGCS2 (-3.45) — ketogenic enzyme, mitochondrial in colonocytes
- DPP10-AS1 (-3.40) — antisense lncRNA
- SLC38A4 (-3.07) — amino acid transporter
- GBA3 (-3.00) — bile acid/cytoplasmic glucosylceramidase
- MEP1B (-2.99) — meprin metalloprotease
- ABCG2 (-2.92) — bile acid efflux transporter
- HSD3B2 (-2.77)
- CYP2B6 (-2.78)
- AQP7 (-2.32)
- SLC16A1 (-2.38) — MCT1, monocarboxylate transporter
- NPY1R (-2.40)
- SLC23A1 (-2.40)
- PITX2 (-2.72)
- DEFB1 (-2.31) — beta-defensin
- APOBEC3B (-2.30)
- HMGCS2 (-3.45)
- UGT2A3 (-2.68)
- CYP2B7P (-2.72)

**Biological themes I'm seeing:**

1. **Neutrophil/innate immune recruitment and inflammation** — CXCL1, CXCL2, CXCL3, IL1RN, IRAK3, SOCS3, S100A8, MMP3, CHI3L1, VNN1, LCN2 — classic neutrophil-driven mucosal inflammation in UC active disease. STRING shows CXCR2 as the shared chemokine receptor axis.

2. **Epithelial barrier dysfunction and antimicrobial defense remodeling** — DEFB1 (defensin) downregulated; DUOX2/DUOXA2 upregulated (oxidative antimicrobial); SERPINB5/maspin upregulated (wound); TNC upregulated (matrix); TRIM29 (epithelial stress/injury); TGM2 (crosslinking, ECM); PDPN (fibroblast/lymphatic marker); PDPN, CDH3 (P-cadherin, immature epithelial phenotype); PI3 (peptidase inhibitor 3, elafin).

3. **Transporter/differentiated enterocyte loss** — major program of downregulated solute carriers and aquaporins: SLC6A14 ↑ (this is opposite, induced by inflammation/IL-22), SLC51A (OSTα) ↓, ABCG2 ↓, SLC38A4 ↓, SLC16A1 (MCT1) ↓, SLC23A1/3 ↓, SLC19A3 ↓, SLC25A34 ↓, AQP8 ↓, AQP7 ↓, G6PC ↓, ABCB11 ↓, UGT2A3 ↓. This is a classic signature of mature colonocyte dedifferentiation/loss with concurrent gain of regenerative/inflammatory transporters. Many of these (SLC51A/OSTα, ABCG2, ABCB11, AQP8, HMGCS2, SLC16A1, G6PC, CYP2B6, HSD3B2, UGT2A3) converge on bile acid handling, water/electrolyte handling, and metabolic functions of mature colonocytes. KEGG "Bile secretion" pathway is hit.

4. **Neutrophil/calprotectin signature (S100A8/S100A8+S100A9 + MMP3 + CHI3L1)** — directly reflects neutrophilic infiltrate, fecal calprotectin biology. CHI3L1 is a well-known UC biomarker candidate.

5. **Mitochondrial β-oxidation/ketogenesis collapse in colonocytes** — HMGCS2, HSD3B2, CYP2B6, ACSF2, ACADM? — energy metabolism down. HMGCS2 is the rate-limiting ketogenic enzyme in colonocytes; loss is associated with UC and DSS colitis. Lipid metabolism/peroxisome also touched.

6. **Wound healing / tissue remodeling / fibrosis** — TNC, TGM2, SERPINB5, PRRX1, PDPN, CDH3, FILIP1L — mesenchyme activation, epithelial-mesenchymal signaling, healing response.

7. **Adaptive immune** — CTLA4, IGHV/IGHG1/IGHM (immunoglobulin transcripts), CD55 (complement regulatory). CD55 (DAF) is a known UC GWAS locus.

8. **LncRNAs/noncoding** — DPP10-AS1, TINCR, CDKN2B-AS1, LOC100290146.

**Pathway/ontology modules retrieved:**
- IL-17 signaling
- Bile secretion
- Rheumatoid arthritis
- Fluid transport
- Water transport
- Carboxylic acid transport

The IL-17 axis fits neutrophil/Th17 inflammation. Bile secretion fits the SLC51A, ABCG2, ABCB11, AQP8, HMGCS2 downregulation (loss of bile acid handling capacity in colonocytes).

**Network modules:**
- CXCR2 ↔ CXCL1, CXCL2, CXCL3 (chemokine-chemokine receptor, STRING physical ligand-receptor, not necessarily direct binding but known biology)
- ITGB1 ↔ FREM2, TGM2, TNC (integrin/ECM module)
- AQP11 ↔ AQP7, AQP8
- AQP12A ↔ AQP7, AQP8
- CCL11 (eotaxin) ↔ CXCL1, CXCL3 (this is STRING neighborhood, mostly co-expression in immune datasets)
- CDH1 ↔ CDH3, S100A8 (co-expression in epithelial injury)

**Key genes to highlight (≤10):**
1. SLC6A14 — strongest up, top signal
2. DUOX2 — redox antimicrobial
3. MMP3 — tissue remodeling
4. S100A8 — calprotectin/neutrophil
5. CHI3L1 — biomarker candidate
6. CXCL1/CXCL2/CXCL3 — CXCR2 axis
7. IL1RN — anti-inflammatory feedback
8. AQP8 — strongest down, mature colonocyte marker
9. SLC51A (OSTα) — bile acid handling
10. HMGCS2 — mitochondrial ketogenesis, well-published UC association
11. SERPINB5 — wound
12. TRIM29 — epithelial injury
13. CD55 — GWAS locus
14. SOCS3 — negative regulator of cytokine signaling

**Validation priorities (≤5):**
1. SLC6A14 / AQP8 / SLC51A as diagnostic biomarker trio for active UC (Biomarker)
2. CXCR2 axis (CXCL1/2/3) as mechanistic/therapeutic target (Mechanistic hypothesis / Therapeutic target) — CXCR2 antagonists exist
3. HMGCS2 restoration in colonocytes (Mechanistic hypothesis)
4. DUOX2/DUOXA2 redox axis (Mechanistic hypothesis)
5. Cell composition confound check — confirm by deconvolution (Confounding check)

**Limitations:**
1. Tissue composition (neutrophil infiltrate inflates innate immune signal)
2. No replication cohort
3. Treatment exposure (steroids, 5-ASA) not addressed
4. Disease activity/severity not stratified
5. Platform/batch effects (some rows are probe IDs)
6. Association vs causation

**Critical notes:**
- The input is DEG only — no enrichment P values, no independent cohort statistics
- Some rows are clearly probe identifiers (PROBE_*, LOC*/*|*) and unclear genes (PP7080, SDR16C5)
- Need to be careful not to overclaim

Let me also think about the GO/KEGG/STRING batch information:
- GO: Fluid Transport, Water Transport, Carboxylic Acid Transport
- KEGG: IL-17 signaling, Bile secretion, Rheumatoid arthritis
- STRING: 50 edges
This is consistent with my interpretation.

Now let me structure the answer following the user's required sections:

1. Overall biological interpretation
2. Core biological programs (≤5)
3. Key genes and interaction modules (≤10)
4. Validation priorities (≤5)
5. Evidence grounding
6. Limitations and alternative explanations

I should be concise but thorough, integrate evidence from the dataset and the evidence pack, distinguish direct evidence from contextual, and clearly mark exploratory vs. supported hypotheses. I should avoid overclaiming and use the literature IDs where relevant.

Let me also think about the literature:
- PMID 41029776: WGCNA + ML UC biomarker study — directly relevant
- PMID 25171508: BRINP3 underexpression in UC pathogenesis — directly relevant
- PMID 38059894: Mendelian randomization + UC treatment response — relevant
- The others are off-topic (T2DM/MAFLD, cattle, neonatal cholestasis, ATase1/NAT8B autism)

Now let me write a careful, evidence-grounded answer. I'll start with a brief data-quality note (the user didn't ask for this explicitly but the prompt instructs me to address data-quality issues) — but only as a brief note since the dataset looks technically clean (all FDR < 0.01, very strong P values).

Actually the instructions say: "If the uploaded statistics are degenerate, saturated, identical, or otherwise technically suspicious, do not stop at an 'insufficient evidence' refusal." The data here are NOT degenerate — they're clean and strong (100 genes, FDR ≤ 1e-10, strong effect sizes). So I can proceed with full interpretation.

But I do need to flag:
- No independent cohort replication available
- Several entries are probe IDs or multi-gene composite rows
- Some lncRNAs/unknown function genes

Let me draft.

Format-wise: The user wants markdown, and asked for very specific sections. I'll structure accordingly.

Let me write the answer now. I'll be careful to:
- Use actual log2FC values from the table
- Not overclaim
- Distinguish evidence types
- Use PMIDs naturally
- End with a complete sentence
- Keep ≤5 programs, ≤10 key genes, ≤5 validation priorities, ≤5 limitations

Let me draft:

# Multidimensional Interpretation: Ulcerative Colitis vs Healthy Colonic Mucosa

## 1. Overall biological interpretation

The DE list is dominated by two opposing, well-coordinated transcriptomic shifts:

- An **upregulated innate-inflammatory / epithelial-stress program**, led by SLC6A14 (log2FC +4.85), DUOX2 (+4.67), MMP3 (+4.64), CHI3L1 (+4.59), S100A8 (+3.80), the CXCL1/CXCL2/CXCL3 chemokine cluster (~+2.3 to +3.5), IL1RN (+2.88), SOCS3 (+2.79), SERPINB5 (+3.29), TRIM29 (+2.83), VNN1 (+3.20), and LCN2 (+2.67). Many of these are neutrophil- or Th17-associated, and many have been flagged individually as UC biomarkers (e.g., CHI3L1, MMP3, S100A8, LCN2).
- A **downregulated mature-colonocyte / transport-metabolic program**, led by AQP8 (−4.42), SLC51A/OSTα (−3.71), HMGCS2 (−3.45), DPP10-AS1 (−3.40), SLC38A4 (−3.07), GBA3 (−3.00), MEP1B (−2.99), ABCG2 (−2.92), HSD3B2 (−2.77), CYP2B6 (−2.78), and several additional SLC/AQP/CYP/UGT transporters (SLC16A1, SLC19A3, SLC23A1/3, AQP7, SLC25A34, ABCB11, UGT2A3, G6PC). Many of these converge on bile-acid handling, water/electrolyte transport, and mitochondrial β-oxidation/ketogenesis in differentiated colonocytes.

Together the picture is of an inflamed, regenerating mucosa that has lost a large fraction of its mature absorptive/secretory/metabolic colonocyte identity while expanding an innate-immune, antimicrobial, and tissue-remodeling response. The retrieved KEGG and GO modules (IL-17 signaling, bile secretion, water/fluid/carboxylic-acid transport) align with this interpretation.

## 2. Core biological programs

I'll list ≤5. Let me pick the most coherent, distinct ones:

**Program 1. CXCR2-driven neutrophil chemotaxis & innate inflammation (upregulated)**
- Direction: upregulated in UC
- Genes: CXCL1 (+3.46), CXCL2 (+2.80), CXCL3 (+2.33), S100A8 (+3.80), MMP3 (+4.64), CHI3L1 (+4.59), LCN2 (+2.67), IL1RN (+2.88), IRAK3 (+1.78), SOCS3 (+2.79), VNN1 (+3.20)
- Pathway: KEGG IL-17 signaling; Hallmark "Inflammatory response"; Reactome neutrophil degranulation
- Why: This is the canonical neutrophil-recruitment cassette. STRING evidence links CXCL1/2/3 as parallel ligands (CXCR2 node, 3 edges), and S100A8 + MMP3 + CHI3L1 are highly correlated neutrophilic markers in UC biopsies and in fecal calprotectin biology.
- Evidence strength: Strong at the individual-gene level (extremely small FDRs, large effect sizes); well-established UC direction from prior literature (e.g., PMID 41029776 biomarker screens). Limitation: cannot distinguish neutrophil-infiltration signal from true epithelial upregulation in bulk tissue without deconvolution; no independent cohort statistic is provided for replication.

**Program 2. Mature colonocyte loss of bile-acid handling, water/electrolyte transport, and mitochondrial ketogenesis (downregulated)**
- Direction: downregulated in UC
- Genes: SLC51A/OSTα (−3.71), ABCG2 (−2.92), ABCB11 (−1.15), HMGCS2 (−3.45), HSD3B2 (−2.77), CYP2B6 (−2.78), CYP2B7P (−2.72), UGT2A3 (−2.68), G6PC (−1.52), GBA3 (−3.00), MEP1B (−2.99), AQP8 (−4.42), AQP7 (−2.32), SLC16A1/MCT1 (−2.38), SLC19A3 (−1.34), SLC23A1 (−2.40), SLC23A3 (−1.93), SLC38A4 (−3.07), SLC25A34 (−1.93)
- Pathway: KEGG Bile secretion; GO "Water transport" (GO:0006833), "Fluid transport" (GO:0042044), "Carboxylic acid transport" (GO:0046942)
- Why: This is the differentiated-colonocyte identity cassette. STRING evidence places AQP7/AQP8 in an aquaporin neighborhood; SLC51A interacts with SLC51B, ABCC3, CYP7A1, SLC10A2, FGF19 (high-confidence edges) — exactly the bile-acid enterohepatic axis. The pattern is highly consistent with published observations that inflamed colonocytes downregulate their solute carriers, AQP8, and HMGCS2 in active UC.
- Evidence strength: Strong (large, concordant effect sizes; biologically coherent module; recurrent across many genes). Limitations: downregulation of "differentiation" markers in inflamed tissue is partly a secondary consequence of epithelial dedifferentiation/regeneration rather than a primary driver; AQP8 expression is also strongly tied to differentiated colonocyte cellularity and could partly reflect epithelial loss.

**Program 3. Epithelial antimicrobial redox response and wound-repair program (mixed)**
- Direction: upregulated
- Genes: DUOX2 (+4.67) / DUOXA2 (+2.89) — NADPH oxidase H2O2 production; SERPINB5/maspin (+3.29), TNC/tenascin-C (+2.58), TGM2 (+1.91), PDPN/podoplanin (+2.54), PRRX1 (+2.91), CDH3/P-cadherin (+2.29), TRIM29 (+2.83), PI3/elafin (+2.21), FILIP1L (+1.86), IGDCC4 (+1.86); downregulated: DEFB1/β-defensin 1 (−2.31), MEP1B (−2.99), AQP7/AQP8 (already counted above)
- Pathway: GO "Extracellular matrix"; KEGG "Rheumatoid arthritis" (mostly because of inflammation/ECM matrix signature)
- Why: A coordinated injury-response: epithelial redox host defense (DUOX2/DUOXA2), defensin downregulation (DEFB1, reflecting deficient Paneth-like/colonic antimicrobial peptide output despite Th17/IL-22 stimulus), and mesenchymal/EMT-like remodeling (TNC, TGM2, PDPN, PRRX1, CDH3). STRING places TNC/TGM2/FREM2 in an ITGB1 (integrin β1) neighborhood — a matrix-receptor module typical of mucosal wound healing.
- Evidence strength: Moderate-to-strong at single-gene level; consistent with known UC tissue remodeling biology. Limitations: the simultaneous up of DUOX2 and down of DEFB1 is mechanistically interesting (oxidative vs peptide antimicrobials diverge), but causal ordering cannot be inferred from association alone.

**Program 4. Adaptive immune / immune-regulatory tone (upregulated)**
- Direction: upregulated
- Genes: IGHV4-31/IGHM/IGHG1/IGH cluster (+1.89, plasma-cell/B-cell transcripts); CTLA4 (+2.62, T-cell checkpoint); SOCS3 (+2.79, cytokine-signaling negative regulator); IL1RN (+2.88, IL-1 decoy); CD55/DAF (+2.04, complement regulatory, also a known UC GWAS locus); IFI16 (+1.39, innate-immune DNA sensor)
- Pathway: Reactome "Interferon signaling" (IFI16); general adaptive-immune compartment.
- Why: This represents the adaptive/regulatory arm of the UC mucosal response: B-cell/plasma-cell expansion (Ig transcripts), checkpoint induction (CTLA4), cytokine-signaling brake (SOCS3), and complement control (CD55). Converges with prior UC GWAS hits at the CD55 locus.
- Evidence strength: Moderate — each gene individually is strong but the program is heterogeneous (mix of activating and regulatory). Limitations: CTLA4 mRNA in the mucosa is hard to interpret without cell-type information (could reflect Treg expansion, or activated conventional T cells).

**Program 5. ncRNAs / uncharacterized regulators**
- Direction: mixed
- Genes: DPP10-AS1 (−3.40), TINCR (−2.04), CDKN2B-AS1 (−2.00), LOC100290146/IGH region (+1.89), LOC102723493 (−1.45)
- Pathway: not classifiable.
- Why: lncRNAs consistently altered in active UC; plausibly regulatory but mechanistically opaque.
- Evidence strength: weak; exploratory only.

That's 5 programs. Good. Program 5 is the weakest, but it's distinct from the rest.

## 3. Key genes / interaction modules (≤10)

1. **SLC6A14** — strongest up (log2FC +4.85). IL-22/Th17-induced amino-acid transporter on inflamed colonocytes; supports bacterial-clearance tryptohan/arginine depletion. Co-expression / pathway co-membership with CXCL chemokines and MMP3 in inflamed-epithelial signatures (literature, PMID 41029776). Not a confirmed physical-interaction hub.

2. **DUOX2 / DUOXA2** (+4.67 / +2.89) — DUOXA2 is the maturation factor required for DUOX2 function; their co-upregulation represents a coordinated redox host-defense module. Direct physical interaction (membrane complex), high-confidence STRING evidence.

3. **CXCL1 / CXCL2 / CXCL3 — CXCR2 axis** — STRING neighborhood edges to CXCR2 (3 ligand edges). Coordinate neutrophil chemotaxis via shared receptor; direct physical ligand–receptor binding, not just co-expression.

4. **S100A8** (+3.80) — heterodimer partner of S100A9 (calprotectin). Co-expression with CDH3 and other injury markers (STRING neighborhood to CDH1); the canonical fecal/blood calprotectin marker, used clinically.

5. **MMP3** (+4.64) — matrix metalloproteinase released by inflamed epithelium and stromal cells. STRING neighborhood with MMP1/MMP7 (not in list). Direct physical substrate (collagen/ECM), regulatory induction by TNF/IL-17.

6. **AQP8** (−4.42) — strongest down; mature colonocyte water/glycerol channel. STRING neighborhood with AQP7/AQP11/AQP12A. Pathway co-membership in "Passive transport by Aquaporins" (Reactome R-HSA-432047) and KEGG Bile secretion.

7. **SLC51A / OSTα** (−3.71) — basolateral bile-acid transporter. STRING: high-confidence interactions with SLC51B, ABCC3, CYP7A1, SLC10A2, FGF19 — i.e., bile-acid enterohepatic axis. Pathway co-membership in "Bile acid and bile salt transport" (GO:0015721) and "Bile secretion" (KEGG).

8. **HMGCS2** (−3.45) — mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2, rate-limiting ketogenic enzyme in colonocytes. Downregulation is well-documented in UC and DSS colitis; pathway co-membership in ketogenesis / PPARα signaling; not in STRING neighborhood with other selected genes at high confidence.

9. **CD55 (DAF)** (+2.04) — complement regulatory protein; UC GWAS susceptibility locus (CD55 rs10794766 etc.); pathway co-membership with complement regulation.

10. **SOCS3** (+2.79) — suppressor of cytokine signaling; negative-feedback on IL-6/STAT3; co-expressed with IL1RN; pathway co-membership in JAK-STAT negative regulation.

That's 10, with interactions explicitly classified.

## 4. Validation priorities (≤5)

1. **CXCR2 axis (CXCL1/2/3 → CXCR2) — therapeutic target**
   - Class: Therapeutic target / mechanistic hypothesis
   - Why: Three large, concordant effect sizes in the same direction; CXCR2 antagonists (e.g., danirixin, reparixin) have clinical precedent in inflammatory disease. Direct dataset evidence: three independent ligands all strongly up.
   - External evidence: IL-17 signaling and neutrophil chemotaxis are well-documented in UC; PMID 41029776 implicates chemokine-axis genes in UC biomarker screens. No independent cohort statistic provided.
   - Next step: CXCR2 inhibition in DSS/IL-10−/− colitis models; mucosal CXCL1/2/3 and neutrophil counts as readouts.
   - Status: Supported hypothesis (association, not causation).

2. **SLC6A14 + AQP8 + SLC51A trio as biomarker for active UC vs remission/healthy**
   - Class: Biomarker
   - Why: Largest effect sizes, opposite directions, and they represent complementary biological compartments (inflamed epithelium vs mature colonocyte).
   - Dataset evidence: SLC6A14 +4.85, AQP8 −4.42, SLC51A −3.71, all FDR < 1e-13.
   - External evidence: Each individually reported as UC biomarker in prior literature; PMID 41029776 supports biomarker-class machine-learning screens.
   - Next step: RT-qPCR / IHC in an independent, well-characterized UC cohort stratified by Mayo endoscopic subscore.
   - Status: Supported hypothesis (needs independent replication; no external cohort statistic provided here).

3. **HMGCS2 restoration in colonocytes — mechanistic hypothesis**
   - Class: Mechanistic hypothesis
   - Why: Strong downregulation (log2FC −3.45) of the rate-limiting ketogenic enzyme in differentiated colonocytes; convergence with the bile-acid/transport program.
   - Dataset evidence: large effect, FDR 1.1e-16; part of a coherent down-program.
   - External evidence: HMGCS2 loss has been reported in UC and in murine colitis; ketogenesis is anti-inflammatory in epithelial contexts.
   - Next step: HMGCS2 conditional rescue (Villin-Cre) in DSS colitis; BHB supplementation readouts.
   - Status: Supported hypothesis; causal direction not established.

4. **DUOX2/DUOXA2 redox–antimicrobial axis**
   - Class: Mechanistic hypothesis
   - Why: Highest redox-transcript signal in the data; coordinated upregulation of DUOX2 and its maturation factor; contrasts with concurrent DEFB1 downregulation.
   - Dataset: log2FC +4.67 / +2.89.
   - External evidence: DUOX2 is a known IFN/IL-17-induced gene in airway and colonic epithelium; PMID-level direct evidence in UC is thinner.
   - Next step: H2O2 measurement in mucosal explants; DUOX2 inhibition in organoid/IBD models.
   - Status: Exploratory hypothesis.

5. **Tissue-composition / neutrophil-infiltration confound check**
   - Class: Confounding or composition check
   - Why: Many "upregulated" genes are neutrophil-derived (S100A8, CXCL1/2/3, MMP3, CHI3L1). The signal could partly reflect neutrophil density rather than colonocyte transcriptional change.
   - Dataset: many of the top-up genes are myeloid/neutrophil markers.
   - External evidence: well-known issue in bulk UC transcriptomics; not addressed here.
   - Next step: deconvolution (CIBERSORTx, EPIC) against colonic scRNA-seq reference; or paired single-cell / spatial transcriptomics.
   - Status: Established methodological caveat.

## 5. Evidence grounding

- **Direct dataset evidence** — the only quantitative evidence for these 100 genes is the user-provided log2FC/P/FDR. All statements about direction and magnitude refer to that.
- **Pathway / ontology evidence** — KEGG Bile secretion, IL-17 signaling, GO water/fluid/carboxylic-acid transport were retrieved from Reactome/QuickGO/KEGG and align with the down- and up-programs. These are contextual annotations, not independent statistical tests in this dataset.
- **Protein / regulatory network evidence** — STRING edges (CXCL1/2/3↔CXCR2, SLC51A↔SLC51B/ABCC3/CYP7A1/SLC10A2/FGF19, AQP7/AQP8 cluster, TNC/TGM2/FREM2↔ITGB1) and OmniPath ligand–receptor (CXCL1/CXCL2↔ADRA2A — note: ADRA2A is the recorded neighbor in OmniPath, not necessarily a physical receptor for these chemokines). Note that OmniPath/STRING-derived neighborhood relationships are not all direct physical interactions; STRING includes co-expression/curated/text-mined edges.
- **Disease-association evidence** — GWAS (100/100 selected items have GWAS records); ClinVar (90/100); OpenTargets (91/100). CD55 is a known UC susceptibility locus; the rest are largely transcriptional, not germline-association evidence.
- **Tissue-specific expression** — GTEx (91/100) and HPA (85/100) provide tissue/cell-type baseline expression context, useful for distinguishing colonocyte vs immune-lineage expression.
- **Therapeutic evidence** — ChEMBL (40/100, many errors) and ClinicalTrials.gov (51/100) and CIViC (7/100) were queried. Existence of a CXCR2 antagonist program is the relevant context for the CXCR2 validation priority. Drug evidence ≠ therapeutic efficacy in UC.
- **Published literature** — Europe PMC / PubMed retrieval produced ~750 / ~936 articles. The most directly relevant are PMID 41029776 (UC biomarker screen), PMID 38059894 (Mendelian randomization + UC treatment response), and PMID 25171508 (BRINP3 underexpression in UC pathogenesis; BRINP3 is in our list at log2FC −2.13). The others (T2DM/MAFLD, cattle, neonatal cholestasis, NAT8B autism) are off-target.
- **Independent cohort validation** — not available. No external statistic was provided; pathway, network, and literature records are not replication.

Conflicts and overlaps:
- The DUOX2/DUOXA2 upregulation vs DEFB1 downregulation is mechanistically interesting: both are antimicrobial peptides/effectors, but they diverge in UC, which is a real biology question (oxidative vs peptide antimicrobial balance).
- The HMGCS2 / AQP8 / SLC51A downregulation and the chemokine/S100A8 upregulation are internally consistent but could each be confounded by loss of mature colonocytes and gain of neutrophils, respectively; this confound is independent of any program.

## 6. Limitations and alternative explanations (≤5)

1. **Tissue / cell-composition confounding** — bulk mucosal RNA conflates epithelium, lamina propria, and infiltrate. Neutrophil-derived transcripts (S100A8, CXCL1/2/3, MMP3, CHI3L1) almost certainly reflect neutrophil infiltration, not just transcriptional regulation in colonocytes. This should be tested by deconvolution against colonic scRNA-seq, or by paired single-cell / spatial data.

2. **No independent cohort validation** — only the supplied DE table is provided; we have no second-cohort statistic. All "concordance" claims rest on prior literature, not on a fresh external test in this dataset.

3. **Treatment exposure / disease activity not controlled** — many patients with active UC are on 5-ASA, steroids, biologics; these drugs independently remodel the transcriptome (especially bile-acid transporters, MMPs, defensins). Severity stratification (Mayo score, endoscopic activity) is also absent. Future studies should match or covariate for treatment and clinical activity.

4. **Platform / probe-level artifacts** — the input includes some rows that are clearly probe identifiers (PROBE_*) and multi-gene composite rows (CYP2B7P|CYP2B6; LOC100290146|IGHV4-31|IGHM|IGHG1|IGH; UBD|GABBR1; C1QTNF3|AMACR; NAT8B|NAT8). These should be cleaned before any downstream claim about a single named gene.

5. **Downregulation of "differentiation" markers is partly secondary** — AQP8, HMGCS2, SLC51A, ABCG2, SLC16A1 are markers of differentiated colonocytes. Their decrease may largely reflect epithelial injury/dedifferentiation rather than primary pathogenic dysfunction; the same effect would occur with any severe colitis. Etiology-specific interpretation requires comparison with Crohn's colitis, infectious colitis, or ischemic colitis controls.

---

End with a complete sentence. Let me close with a final integration sentence.

OK let me also double-check the counts. The user said:
- 40 upregulated, 60 downregulated
- 100 unique genes
- 175 input rows retained (43 duplicates)

My counts seem right.

Let me also think — did I miss any major programs?
- Wnt signaling — PITX2 is down; Wnt would generally be up in regenerating mucosa. Not a dominant signal here.
- PPARα / fatty-acid oxidation — HMGCS2, ACSF2, HSD3B2 fit; I included this under Program 2.
- Complement — CD55 only, included in Program 4.
- Th17/IL-22 — would expect IL22, IL17A/F, IL23R, STAT3 target genes; not in the list but the program signature is implied by the chemokines + SOCS3.

Five programs is right.

Let me also verify the literature statements carefully:
- PMID 41029776: I see it in PubMed and Europe PMC, described as UC biomarker screening — that's fair.
- PMID 38059894: Europe PMC, "Comprehensive analysis reveals key genes and environmental toxin exposures underlying treatment response in ulcerative colitis based on in-silico analysis and Mendelian randomization." That's treatment-response MR, fair.
- PMID 25171508: "Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis." BRINP3 is in our list (log2FC −2.13). This is a directly relevant piece of independent evidence.

Good. Let me finalize the response.

One more thing — the user prompt mentioned the GO/KEGG/STRING batch gave these:
- GO: Fluid Transport (GO:0042044), Water Transport (GO:0006833), Carboxylic Acid Transport (GO:0046942)
- KEGG: IL-17 signaling pathway, Bile secretion, Rheumatoid arthritis
- STRING edges: 50

I'll reference these.

Also the recurrent pathway/ontology modules in the synthesis context:
- molecular_function (82 genes)
- biological_process (69 genes)
- MF:protein binding (56 genes)
- CC:plasma membrane (12 genes), CC:extracellular region (11 genes), CC:membrane (11 genes), CC:cytoplasm (9 genes)

These are very broad GO terms, not particularly informative. The more specific ones (IL-17, bile secretion, water transport) are more useful and I use those.

Now let me write this out cleanly. I'll be careful about length — the user wants a substantive answer but not bloated.

Actually, re-reading the instructions: "Do not optimize the response for length or the number of biological concepts mentioned." So I should prioritize substance over coverage. Let me keep it tight.

Final check on the programs — I have 5:
1. CXCR2-driven neutrophil chemotaxis & innate inflammation (up)
2. Mature colonocyte loss of bile-acid handling, water/electrolyte transport, mitochondrial ketogenesis (down)
3. Epithelial antimicrobial redox response and wound-repair program (mixed)
4. Adaptive immune / immune-regulatory tone (up)
5. ncRNAs / uncharacterized regulators (mixed)

These are reasonably non-redundant. Good.

Key genes (10):
1. SLC6A14
2. DUOX2/DUOXA2
3. CXCL1/2/3 (CXCR2 axis)
4. S100A8
5. MMP3
6. AQP8
7. SLC51A
8. HMGCS2
9. CD55
10. SOCS3

That's exactly 10.

Validation priorities (5):
1. CXCR2 axis — therapeutic
2. SLC6A14/AQP8/SLC51A trio — biomarker
3. HMGCS2 restoration — mechanistic
4. DUOX2/DUOXA2 redox — mechanistic
5. Tissue composition confound check

5. Good.

Limitations (5):
1. Cell composition
2. No replication cohort
3. Treatment/severity not controlled
4. Probe-level artifacts
5. Down markers may reflect dedifferentiation not primary

5. Good.

OK, writing the final answer now.</think>

# Multidimensional interpretation: ulcerative colitis vs healthy colonic mucosa

## 1. Overall biological interpretation

The differential-expression (DE) list reflects two opposing, well-coordinated transcriptomic shifts:

- **An upregulated innate-inflammatory / epithelial-stress program**, led by *SLC6A14* (log2FC +4.85), *DUOX2* (+4.67), *MMP3* (+4.64), *CHI3L1* (+4.59), *S100A8* (+3.80), the *CXCL1/CXCL2/CXCL3* chemokine cluster (~+2.3 to +3.5), *IL1RN* (+2.88), *SOCS3* (+2.79), *SERPINB5* (+3.29), *TRIM29* (+2.83), *VNN1* (+3.20) and *LCN2* (+2.67). Many are neutrophil- or Th17-associated, and several are individually reported as UC biomarkers (e.g., *CHI3L1*, *MMP3*, *S100A8*, *LCN2*).
- **A downregulated mature-colonocyte transport-metabolic program**, led by *AQP8* (−4.42), *SLC51A/OSTα* (−3.71), *HMGCS2* (−3.45), *SLC38A4* (−3.07), *GBA3* (−3.00), *MEP1B* (−2.99), *ABCG2* (−2.92), *HSD3B2* (−2.77), *CYP2B6* (−2.78), *AQP7* (−2.32), *SLC16A1/MCT1* (−2.38), and additional SLC/AQP/CYP/UGT solute carriers (*SLC19A3*, *SLC23A1/3*, *SLC25A34*, *ABCB11*, *UGT2A3*, *G6PC*). These converge on bile-acid handling, water/electrolyte transport, and mitochondrial β-oxidation/ketogenesis in differentiated colonocytes.

The retrieved ontology/KEGG modules (IL-17 signaling; bile secretion; GO water/fluid/carboxylic-acid transport) align with this picture. The overall biology is an inflamed, regenerating mucosa that has lost a large share of its mature absorptive/secretory/metabolic colonocyte identity while expanding an innate-immune, antimicrobial, and tissue-remodeling response. **No independent cohort replication statistic is supplied**, so all "concordance" statements below rely on prior published literature, not on a second dataset.

## 2. Core biological programs (≤5)

**Program 1 — CXCR2-driven neutrophil chemotaxis & innate inflammation (upregulated).**
- Direction in UC: up.
- Supporting genes: *CXCL1* (+3.46), *CXCL2* (+2.80), *CXCL3* (+2.33), *S100A8* (+3.80), *MMP3* (+4.64), *CHI3L1* (+4.59), *LCN2* (+2.67), *IL1RN* (+2.88), *IRAK3* (+1.78), *SOCS3* (+2.79), *VNN1* (+3.20).
- Pathway: KEGG "IL-17 signaling pathway"; Hallmark "Inflammatory response"; Reactome neutrophil degranulation.
- Rationale: canonical neutrophil-recruitment cassette. STRING places *CXCL1/2/3* as parallel CXCR2 ligands (3 edges). *S100A8*, *MMP3*, *CHI3L1*, *LCN2* are well-correlated neutrophilic markers in UC biopsies (fecal-calprotectin biology).
- Strength & limits: very strong at single-gene level (FDR < 1e-13 throughout); direction is well-established in UC literature (e.g., PMID 41029776 UC biomarker screen). Without deconvolution, the signal cannot be cleanly partitioned between infiltrated neutrophils and inflamed epithelium.

**Program 2 — Mature colonocyte loss: bile-acid handling, water/electrolyte transport, mitochondrial ketogenesis (downregulated).**
- Direction in UC: down.
- Supporting genes: *SLC51A/OSTα* (−3.71), *ABCG2* (−2.92), *ABCB11* (−1.15), *HMGCS2* (−3.45), *HSD3B2* (−2.77), *CYP2B6* (−2.78), *CYP2B7P* (−2.72), *UGT2A3* (−2.68), *G6PC* (−1.52), *GBA3* (−3.00), *MEP1B* (−2.99), *AQP8* (−4.42), *AQP7* (−2.32), *SLC16A1/MCT1* (−2.38), *SLC19A3* (−1.34), *SLC23A1* (−2.40), *SLC23A3* (−1.93), *SLC38A4* (−3.07), *SLC25A34* (−1.93).
- Pathway: KEGG "Bile secretion"; GO "Water transport" (GO:0006833), "Fluid transport" (GO:0042044), "Carboxylic acid transport" (GO:0046942).
- Rationale: differentiated-colonocyte identity cassette. STRING shows high-confidence *SLC51A–SLC51B*, *SLC51A–ABCC3*, *SLC51A–CYP7A1*, *SLC51A–SLC10A2*, *SLC51A–FGF19* edges — the enterohepatic bile-acid axis. *AQP7/AQP8* cluster with *AQP11/AQP12A*; Reactome places *AQP8* in "Passive transport by Aquaporins" (R-HSA-432047) and KEGG "Bile secretion".
- Strength & limits: strong, coherent, large effect sizes. Limitation: downregulation of differentiation markers is at least partly secondary to epithelial dedifferentiation/regeneration rather than a primary driver, and *AQP8* expression is tightly tied to mature colonocyte cellularity.

**Program 3 — Epithelial antimicrobial redox response and wound-repair (mixed).**
- Direction in UC: predominantly up, with one defensin down.
- Supporting genes: *DUOX2* (+4.67)/ *DUOXA2* (+2.89) — H2O2-generating NADPH oxidase and its maturation factor; *SERPINB5/maspin* (+3.29), *TNC/tenascin-C* (+2.58), *TGM2* (+1.91), *PDPN/podoplanin* (+2.54), *PRRX1* (+2.91), *CDH3/P-cadherin* (+2.29), *TRIM29* (+2.83), *PI3/elafin* (+2.21), *FILIP1L* (+1.86), *IGDCC4* (+1.86); *DEFB1/β-defensin 1* (−2.31) is downregulated.
- Pathway: GO "extracellular matrix"; KEGG "Rheumatoid arthritis" (shared ECM/inflammation signature); Reactome "Detoxification of Reactive Oxygen Species" for *AQP8/DUOX* neighborhood.
- Rationale: a coordinated injury response — epithelial redox host defense (DUOX2/DUOXA2), peptide antimicrobial deficiency (DEFB1), and mesenchyme/ECM activation (TNC, TGM2, PDPN, PRRX1, CDH3). STRING places *TNC*, *TGM2*, *FREM2* in an *ITGB1* (integrin-β1) neighborhood — a classic matrix-receptor module in mucosal healing.
- Strength & limits: moderate-to-strong single-gene evidence; consistent with known UC remodeling. The opposite directions of *DUOX2* (oxidative antimicrobial up) vs *DEFB1* (peptide antimicrobial down) is mechanistically interesting and cannot be explained away.

**Program 4 — Adaptive/regulatory immune tone (upregulated).**
- Direction in UC: up.
- Supporting genes: *IGHV4-31/IGHM/IGHG1/IGH* cluster (+1.89; plasma-cell/B-cell Ig transcripts), *CTLA4* (+2.62), *SOCS3* (+2.79), *IL1RN* (+2.88), *CD55/DAF* (+2.04), *IFI16* (+1.39).
- Pathway: Reactome "Interferon signaling"; broader adaptive-immune compartment.
- Rationale: the adaptive arm — plasma-cell expansion (Ig transcripts), checkpoint induction (*CTLA4*), cytokine-signaling brake (*SOCS3*), complement control (*CD55* — also a known UC GWAS locus).
- Strength & limits: moderate; the program is heterogeneous (activating and regulatory mixed). *CTLA4* mRNA in bulk mucosa is hard to interpret without cell-type information.

**Program 5 — lncRNAs / uncharacterized regulators (mixed).**
- *DPP10-AS1* (−3.40), *TINCR* (−2.04), *CDKN2B-AS1* (−2.00), *LOC100290146/IGH* (+1.89), *LOC102723493* (−1.45).
- Status: exploratory only; no clear pathway co-membership in retrieved ontology.

## 3. Key genes and interaction modules (≤10)

| # | Gene (direction, log2FC) | Role in programs | Relationship type |
|---|---|---|---|
| 1 | *SLC6A14* (up, +4.85) | Inflamed-epithelium amino-acid transporter, IL-22-induced | Co-expression / pathway co-membership with CXCL/MMP3 cassettes in UC biomarker studies (PMID 41029776); not a confirmed physical-interaction hub |
| 2 | *DUOX2* (up, +4.67) / *DUOXA2* (up, +2.89) | Redox antimicrobial module (Program 3) | **Direct physical interaction** (DUOXA2 is the DUOX2 maturation factor) |
| 3 | *CXCL1*/*CXCL2*/*CXCL3* (up, +3.46 / +2.80 / +2.33) | Neutrophil chemotaxis via CXCR2 (Program 1) | **Direct physical ligand–receptor binding** to CXCR2 (STRING, 3 ligand edges) |
| 4 | *S100A8* (up, +3.80) | Calprotectin component, neutrophil marker (Program 1) | Heterodimer physical partner with S100A9; STRING co-expression with *CDH3* (CDH1 neighborhood) |
| 5 | *MMP3* (up, +4.64) | ECM remodeling (Programs 1 & 3) | Direct enzymatic substrate; STRING neighborhood with other MMPs |
| 6 | *AQP8* (down, −4.42) | Mature colonocyte water/bile channel (Program 2) | STRING neighborhood with *AQP7*, *AQP11*, *AQP12A*; Reactome R-HSA-432047 "Passive transport by Aquaporins" |
| 7 | *SLC51A/OSTα* (down, −3.71) | Basolateral bile-acid transporter (Program 2) | **Direct physical interactions** (STRING, high confidence): *SLC51B* (0.999), *ABCC3* (0.913), *CYP7A1* (0.903), *SLC10A2* (0.883), *FGF19* (0.873) |
| 8 | *HMGCS2* (down, −3.45) | Mitochondrial ketogenesis in colonocytes (Program 2) | Pathway co-membership in ketogenesis / PPARα signaling; no high-confidence STRING edge to other selected genes |
| 9 | *CD55/DAF* (up, +2.04) | Complement regulation (Program 4); UC GWAS locus | Genetic/clinical (GWAS) evidence + pathway co-membership |
| 10 | *SOCS3* (up, +2.79) | Negative feedback on JAK-STAT / IL-6 (Programs 1 & 4) | Regulatory interaction (cytokine-signaling brake); co-expression with *IL1RN* |

Co-expression, pathway co-membership, and STRING neighborhood are explicitly **not** equivalent to direct physical interaction except where stated. The OmniPath "ADRA2A" adjacency of *CXCL1/2* is a database neighborhood record, not a validated receptor for these chemokines.

## 4. Validation priorities (≤5)

1. **CXCR2 axis as therapeutic target (CXCL1/2/3 → CXCR2).** *Class: Therapeutic target / mechanistic hypothesis.* Three independent ligands all strongly upregulated in the same direction in one dataset is exactly the signal that justifies target nomination. External context: CXCR2 antagonists (e.g., danirixin, reparixin) have been tested in inflammatory disease. **Next step**: CXCR2 blockade in DSS or IL-10−/− colitis with mucosal CXCL1/2/3 and neutrophil counts as readouts. **Status: Supported hypothesis** (single-cohort association, not causal).

2. **SLC6A14 + AQP8 + SLC51A trio as biomarker for active UC vs healthy/remission.** *Class: Biomarker.* Three largest effect sizes in opposite directions, covering complementary compartments (inflamed epithelium vs mature colonocyte). **Next step**: RT-qPCR / IHC in an independent cohort stratified by Mayo endoscopic subscore. **Status: Supported hypothesis** (no independent replication provided here; PMID 41029776 supports the broader biomarker screen concept).

3. **HMGCS2 restoration in colonocytes.** *Class: Mechanistic hypothesis.* Strong downregulation (FDR 1e-16) of the rate-limiting ketogenic enzyme in differentiated colonocytes; converges with the bile-acid/transport loss program. **Next step**: Villin-Cre-driven HMGCS2 rescue in DSS colitis, with β-hydroxybutyrate supplementation as orthogonal arm. **Status: Supported hypothesis**; direction of causality not established.

4. **DUOX2/DUOXA2 redox–antimicrobial axis.** *Class: Mechanistic hypothesis.* Highest redox-transcript signal in the data, coordinated upregulation of *DUOX2* and its maturation factor; contrasts with *DEFB1* downregulation. **Next step**: H2O2 measurement in mucosal explants; DUOX2 inhibition in colonic organoids under inflammatory cytokine challenge. **Status: Exploratory hypothesis**.

5. **Tissue-composition confound check.** *Class: Confounding or composition check.* Many of the largest "up" genes are neutrophil-derived (*S100A8*, *CXCL1/2/3*, *MMP3*, *CHI3L1*, *LCN2*); the signal may partly reflect infiltrate density, not colonocyte transcriptional change. **Next step**: CIBERSORTx / EPIC deconvolution against colonic scRNA-seq, or paired single-cell / spatial transcriptomics, ideally matched to histology-based neutrophil counts. **Status: Established methodological caveat**.

> Caveat: the existence of drugs against *CXCR2*, *MMP3*, *SOCS3* or *JAK* pathways does not, on its own, demonstrate therapeutic efficacy in UC.

## 5. Evidence grounding

- **Direct dataset evidence** — the only quantitative evidence for these 100 genes is the user-supplied log2FC / P / FDR. All direction and magnitude statements above are anchored to that table.
- **Pathway / ontology evidence** — KEGG Bile secretion and IL-17 signaling; GO water / fluid / carboxylic-acid transport are contextual annotations retrieved from Reactome, QuickGO and KEGG. They align with the two dominant programs but are not independent statistical tests in this dataset.
- **Protein / regulatory network evidence** — STRING (85/100 selected genes returned), OmniPath (45/100), TRRUST (31/100). The strongest physical edges are the *CXCL1/2/3–CXCR2* ligand–receptor set and the *SLC51A–SLC51B/ABCC3/CYP7A1/SLC10A2/FGF19* bile-acid axis. STRING also provides *AQP7/AQP8/AQP11/AQP12A* neighborhood and the *TNC/TGM2/FREM2* ITGB1 neighborhood. STRING and OmniPath edges may include text-mined/co-expression relationships and are not all direct physical interactions.
- **Disease / genetic / clinical evidence** — GWAS (100/100), ClinVar (90/100), OpenTargets (91/100), ClinicalTrials.gov (51/100) records were returned. The most directly relevant genetic hit is *CD55*, a known UC susceptibility locus. The remaining associations are predominantly transcriptional rather than germline-based.
- **Tissue / cell-type evidence** — GTEx (91/100) and Human Protein Atlas (85/100) provide baseline tissue expression context; useful for separating colonocyte vs immune-lineage transcripts.
- **Therapeutic evidence** — ChEMBL (40/100 returned, many query errors), ClinicalTrials.gov (51/100), CIViC (7/100). Drug-target presence is recorded but is not equivalent to efficacy in UC.
- **Published literature** — ~750 PubMed and ~936 Europe PMC records were retrieved. Three are directly relevant to this dataset: PMID **41029776** (WGCNA + ML UC biomarker screen), PMID **38059894** (Mendelian randomization + UC treatment response), and PMID **25171508** (*BRINP3* underexpression in UC pathogenesis — *BRINP3* is in our list at log2FC −2.13, providing one genuinely independent gene-level piece of supporting evidence). The other retrieved items (T2DM/MAFLD, cattle body size, neonatal *ABCB11* cholestasis, *NAT8B* autism mouse model) are off-target and do not support UC-specific claims.
- **Independence caveat** — sources within the same evidence class often share underlying publications, ontology curation, or model predictions and should not be counted as fully independent replications.

Conflicts and overlaps:
- *DUOX2/DUOXA2* up vs *DEFB1* down is a genuine directional divergence within the antimicrobial compartment, not a contradiction; it likely reflects the relative contributions of oxidative vs peptide antimicrobials in active UC.
- Neutrophil-infiltration signal (Program 1) and loss-of-colonocyte signal (Program 2) are independently coherent but each is partly compositional; this is a confound, not a contradiction.

## 6. Limitations and alternative explanations (≤5)

1. **Tissue / cell-composition confounding.** Bulk mucosal RNA conflates epithelium, lamina propria, and infiltrate; *S100A8*, *CXCL1/2/3*, *MMP3*, *CHI3L1* and *LCN2* are largely neutrophil-derived. This should be partitioned by deconvolution against colonic scRNA-seq or paired single-cell / spatial data before claiming colonocyte-intrinsic regulation.
2. **No independent cohort replication is supplied.** Concordance statements rely on prior literature, not on a second dataset. Inferences about robustness are correspondingly softer.
3. **Treatment exposure and disease activity are not controlled.** Many UC patients are on 5-ASA, corticosteroids, immunomodulators or biologics, each of which independently remodels bile-acid transporters, MMPs, defensins and chemokines. Severity (Mayo endoscopic subscore, histology) is not stratified here.
4. **Probe-level and multi-gene row artifacts.** Several input rows are clearly probe identifiers (PROBE_*) or composite rows (*CYP2B7P|CYP2B6*; *LOC100290146|IGHV4-31|IGHM|IGHG1|IGH*; *UBD|GABBR1*; *C1QTNF3|AMACR*; *NAT8B|NAT8*). These should be cleaned before any single-gene causal claim, and the lncRNA/*LOC* rows should be treated as exploratory until individually validated.
5. **Differentiation-marker downregulation is partly secondary.** *AQP8*, *HMGCS2*, *SLC51A*, *ABCG2* and *SLC16A1* are mature-colonocyte markers; their decrease may largely reflect epithelial injury / dedifferentiation rather than primary pathogenic dysfunction. The same signature would be expected in non-UC severe colitis; etiology-specific claims require comparison with Crohn's colitis, infectious, or ischemic colitis controls.

These program-level patterns and candidate genes form a coherent, evidence-anchored working model of the inflamed UC mucosa: neutrophil- and Th17-driven inflammation superimposed on collapse of mature-colonocyte bile-acid, water and metabolic identity, with an active epithelial redox and wound-repair response layered on top.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=1, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
